OpenAI recently developed a new AI micro model, GPT-4b, in collaboration with Retro Biosciences, a longevity startup, to improve the efficiency of stem cell production.
In the past, the contribution of AI in bioengineering was limited to the prediction of protein structures by Google’s Deepmind. However, this model is supposedly said to enhance longevity science, expanding the horizons of life beyond the threshold limit.
The GPT-4b model, as claimed by researchers at OpenAI, can visualize proteins that are capable of transforming regular cells into stem cells. Custom-built for biological research, this model is expected to streamline the Yamanaka factor, a protein that modifies human skin cells.
The Yamanaka factor represents four special genes that can significantly optimize cellular operations. It is responsible for resetting a cell to its factory settings.
Read More: Anthropic Upgrades Claude 3.5 Sonnet
Backed by Sam Altman—CEO of OpenAI—Retro, Biosciences looks forward to developing regenerative medicine that can supply cell replacement to combat age-related diseases.
The GPT-4b model is trained on various protein species and how proteins interact inside a living body. Although the training is conducted on massive datasets, this model is comparatively smaller than other OpenAI models, making it a small language model (SLM).
According to the MIT Technology Review Report, it has been almost a year since Retro Biosciences reached out to OpenAI for this protein engineering project. Sam Altman is said to have already funded a total of $180 million to support Retro Biosciences’ purpose of biological enhancement.
This project aims to revolutionize artificial general intelligence (AGI), broadening the domain of AI applications to medicine.